Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: Assessments based on controlled treatment trials in patients with neurological diseases

Muscle and Nerve

Volumn 20, Issue 9, 1997, Pages 1102-1107

  Koffman, Boyd M ^a   Dalakas, Marinos C ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Intravenous immunoglobulin; T cell subsets; Transient lymphopenia

Indexed keywords

CREATINE KINASE; IMMUNOGLOBULIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; HYPOMAGNESEMIA; HYPONATREMIA; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTOPENIA; NEUROMUSCULAR DISEASE; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

ADULT; BLOOD; BLOOD CELLS; BLOOD SEDIMENTATION; CHILD; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; NEUROMUSCULAR DISEASES; RETROSPECTIVE STUDIES;

EID: 0030753782     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4598(199709)20:9<1102::AID-MUS2>3.0.CO;2-C     Document Type: Article

References (16)

1. Arsura EL, Bick A, Brunner NG, Namba T, Grob D: High dose intravenous immunoglobulin in the management of myasthenia gravis. Arch Intern Med 1986;146:1365-1368.
2. Ashan N, Palmer BF, Wheeler D, Greenlee RG, Toto RD: Intravenous immunoglobulin-indticed osmotic nephrosis. Arch Intern Med 1994;154:1985-1987.
3. Ballow M: Mechanisms of action of intravenous immunoglobiilin therapy and potential use in autoimmune connective tissue diseases. Cancer 1991;68(suppl):1430-1436.
4. Basta M, Dalakas MC: High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994;94:1729-1735.
5. Basta M, Kirshbom P, Frank MM, Fries LF: Mechanism of therapeutic effect of high dose intravenous immunoglobulin: attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest 1989;84:1974-1981.
6. Blick KE, Liles SM: Principles of Clinical Chemistry. New York, Wiley, 1985, pp 401-404.
7. Bower LR III, Brey RL, Rogers SJ, Stroncek DF, Jackson CE: Intravenous immunoglobulin-induced neutropenia [abstract]. Ann Neural 1994;36:291.
8. Buckley RH, Schiff RI: The use of intravenous immunoglobulin in immunodeficiency diseases. N Engl J Med 1991;325: 110-117.
9. Chaudhry V, Corse AM, Cornblath DR, Kuncl RW, Drachman DB, Freimer ML, et al.: Multifocal motor neuropathy: response to human immune globulin. Ann Neural 1993;33: 237-242.
10. Cook D, Dalakas M, Galdi A, Biondi D, Porter H: High dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology 1990;40:212-214.
11. Cook L, Howard JF, Folds JD: Immediate effects of intravenous IgG administration on peripheral blood B and T cells and polymorphonuclear cells in patients with myasthenia gravis. J Clin Immunol 1988;8:23-31.
12. Dalakas MC: High dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994;44:223-226.
13. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S: A controlled trial of high-dose intravenous immune globulin infusions as a treatment for dermatomyositis. N Engl J Med 1993;329:1993-2000.
14. Dalakas MC: Intravenous immunoglobulin therapy for neurological disease. Ann Intern Med 1997;126:721-730.
15. Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, Baumgartner C, Morell A, Schoni M, Wagner HP: A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neural 1994;36:838-845.
16. Imbach P, d'Apuzzo V, Hirt A, Rossi E, Vest M, Barandun S, et al.: High dose intravenous gammaglobulin therapy for idiopathic thrombocytopenia purpura in childhood. Lancet 1981;i:1228-1230.